Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Report Highlights

The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%.

Report Includes

• An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
• Analyses of global market trends, with data from 2012, 2016, and projections of compound annual growth rates (CAGRs) through 2021
• Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
• Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
• Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
• Evaluation of prostate cancer treatment products by geography, race, and category
• Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
• Comprehensive company profiles of major players in the field.

Report Scope

The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments.

Screening for diagnosis, therapy via drug, surgery or radiation is measured and broken down by PSA testing, digital rectal exam (DRE), prostate biopsy, hormone therapy, chemotherapy, immunotherapy, external beam radiation therapy (EBRT), prostatectomy and brachytherapy.

Analyst Credentials

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.